News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Insider Information

Centers for Medicare & Medicaid Services publish preliminary rate of $192 for Epigenomics’ colorectal cancer screening test Epi proColon®

PDF June 9, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced today that the Centers for Medicare & Medicaid Services (CMS) published a preliminary rate of $192 per Epi proColon test. Epi proColon is the first and only FDA-approved blood-based test for colorectal cancer screening. A press release with further details will be […]

Read more

Epigenomics AG: American Cancer Society published its updated colorectal cancer screening guidelines

PDF May 30, 2018 – Epigenomics AG announces that the Company’s blood-based colorectal cancer test Epi proColon® is not included in the updated colorectal cancer screening guidelines of the American Cancer Society published today. The Company will continue to pursue its goal to provide the significant unscreened patient population in the United States access to this […]

Read more

Epigenomics AG: Notice of Loss pursuant to § 92 par. 1 AktG

PDF Publication of Inside Information according to Article 17 MAR Epigenomics AG: Notice of Loss pursuant to § 92 par. 1 AktG April 17, 2018 – The Executive Board of Epigenomics AG (FSE: ECX; OTCQX: EPGNY) notifies that according to its best judgment a cumulative loss of more than half of the nominal share capital of […]

Read more

Epigenomics AG issues new shares by way of private placement

PDF Publication of Inside Information according to Article 17 MAR Not for distribution in the United States of America Berlin, Germany, September 20, 2017 – Epigenomics AG, Berlin, Germany (Frankfurt Prime Standard: ECX, ISIN: DE0000A11QW50), announces that the Company is raising approximately EUR 5.5 million of gross proceeds in a share capital increase by way of private […]

Read more

Epigenomics AG: Notice of Loss pursuant to § 92 par. 1 AktG

PDF Publication of Inside Information according to Article 17 MAR August 7, 2017 – The Executive Board of Epigenomics AG (FSE: ECX; OTCQX: EPGNY) notifies that according to its best judgment a cumulative loss of more than half of the nominal share capital of the company has been incurred. This is mainly attributable to budgeted losses […]

Read more

Epigenomics AG issues change in guidance for financial year 2017

PDF July 6, 2017 – Epigenomics AG (FSE: ECX; OTCQX: EPGNY) today lowered its financial outlook for the financial year 2017. Based on lower than expected revenues in the first half of 2017 (H1 2017: approximately EUR 0.5 million), and the continued lack of reimbursement coverage anticipated for the remainder of the year in the U.S. […]

Read more
...